Sfoglia per AUTORE
CUTAIA O
Collezione ASL Vercelli

  

Items : 4

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2013 Oct;14(11):1104-1111. doi: 10.1016/S1470-2045(13)70381-4. Epub 2013 Sep 11.

2013
ASL Vercelli

Morra A; Calabrò L; Fonsatti E; Cutaia O; Amato G; Giannarelli D; Di Giacomo AM; Danielli R; Altomonte M; Mutti L; Maio M;

A phase II study with the anti-CTLA-4 mab tremelimumab in chemotherapy-resistant advanced malignant mesothelioma safety, tolerability, clinical and immunologic activity in Journal of Immunotherapy

2011
ASL Vercelli

Calabrò L; Fonsatti E; Di Giacomo AM; Morra A; Cutaia O; Danielli R; Altomonte M; Mutti L; Maio M;

Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: Immunotherapeutic implications in Journal of Cellular Physiology

2011
ASL Vercelli

Calabrò L; Sigalotti L; Fonsatti E; Bertocci E; Di Giacomo AM; Danielli R; Cutaia O; Colizzi F; Covre A; Mutti L; Natali PG; Maio M;

A phase II study with the anti-CTLA-4 mAb tremelimumab in chemotherapy-resistant advanced malignant mesothelioma: Safety, tolerability, clinical and immunologic activity in Journal of Thoracic Oncology

2011
ASL Vercelli

Calabrò L; Di Giacomo AM; Morra A; Cutaia O; Fonsatti E; Danielli R; Altomonte M; Mutti L; Maio M;